Virios Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch VIRI and buy or sell other stocks, ETFs, and their options commission-free!

About VIRI

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. 

CEO
Gregory Duncan, MBA
CEOGregory Duncan, MBA
Employees
8
Employees8
Headquarters
Alpharetta, Georgia
HeadquartersAlpharetta, Georgia
Founded
Founded
Employees
8
Employees8

VIRI Key Statistics

Market cap
130.31M
Market cap130.31M
Price-Earnings ratio
-0.13
Price-Earnings ratio-0.13
Dividend yield
—
Dividend yield—
Average volume
86.12K
Average volume86.12K
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$7.04
52 Week high$7.04
52 Week low
$1.13
52 Week low$1.13

Stock Snapshot

Virios Therapeutics(VIRI) stock is priced at $3.88, giving the company a market capitalization of 130.31M. It carries a P/E multiple of -0.13.

During the trading day, Virios Therapeutics(VIRI) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 86.12K.

The stock's 52-week range extends from a low of $1.13 to a high of $7.04.

The stock's 52-week range extends from a low of $1.13 to a high of $7.04.

People also own

Based on the portfolios of people who own VIRI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.